Who has been buying Dongsung Pharmaceutical stock?

0 distinct insiders have filed 0 disclosed insider purchases in Dongsung Pharmaceutical (002210), most recently on 2026-04-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.

How many insider filings does Dongsung Pharmaceutical have?

Dongsung Pharmaceutical has 0 buy-side and 0 sell-side disclosures on record, spanning 2022-10-13 to 2026-04-09.

Do insider buys in Korean stocks predict returns?

Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Dongsung Pharmaceutical 002210

Company

동성제약Dongsung Pharmaceutical

Insiders

Buys

Total Value

—

Avg Return

—

Last Filing

2026-04-09

Dongsung Pharmaceutical (002210) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Dongsung Pharmaceutical is dated 2022-10-13; the most recent is 2026-04-09.

Price & insider activity (12 months)

Recent insider trades

Date	Type	Source	Insider	Position	Shares	Price at filing	Return	Value
2026-04-09	BUY	CB인수	태광산업 Taekwang Industry	-	10.0M	₩973	+0.0%	₩9.7B ($6.8M)
2026-04-09	BUY	CB인수	아이비케이금융그룹-유암코 중기도약 펀드 IBC Financial Group-Yuamco Mid-Term Jump Fund	-	8.5M	₩973	+0.0%	₩8.3B ($5.7M)
2026-04-09	BUY	CB인수	유암코제약산업제1호기업재무안정사모투자 Yuamco Pharmaceutical Industry No. 1 Corporate Financial Stability Private Investment	-	31.5M	₩973	+0.0%	₩30.6B ($21.3M)
2026-03-31	BUY	제3자배정유상증자	유암코제약산업제1호기업재무안정사모투자 Yuamco Pharmaceutical Industry No. 1 Corporate Financial Stability Private Investment	-	31.5M	₩973	+0.0%	₩30.6B ($21.3M)
2026-03-31	BUY	제3자배정유상증자	아이비케이금융그룹-유암코 중기도약 펀드 IBC Financial Group-Yuamco Mid-Term Jump Fund	-	8.5M	₩973	+0.0%	₩8.3B ($5.7M)
2026-03-31	BUY	제3자배정유상증자	태광산업 Taekwang Industry	-	30.0M	₩973	+0.0%	₩29.2B ($20.3M)
2025-06-24	SELL	기타	나원균 Na Won-gyun	CEO	-300.0K	₩973	+0.0%	₩292M ($203K)
2025-04-22	BUY	장외매수	브랜드리팩터링 Brand refactoring	-	1.6M	₩1,885	-48.4%	₩3.0B ($2.1M)
2025-04-21	BUY	장외매수	브랜드리팩터링 Brand refactoring	-	1.3M	₩1,910	-49.1%	₩2.4B ($1.7M)
2025-02-26	SELL	장외매도	이양구 Lee Yang-gu	-	-766.4K	₩1,950	+50.1%	₩1.5B ($1.0M)
2025-02-26	BUY	장외매수	나원균 Na Won-gyun	moving	766.4K	₩1,950	-50.1%	₩1.5B ($1.0M)
2022-10-13	SELL	증여	이양구 Lee Yang-gu	-	-300.0K	₩3,445	+71.8%	₩1.0B ($718K)

Frequently asked questions

Who has been buying Dongsung Pharmaceutical stock?: 0 distinct insiders have filed 0 disclosed insider purchases in Dongsung Pharmaceutical (002210), most recently on 2026-04-09. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Dongsung Pharmaceutical have?: Dongsung Pharmaceutical has 0 buy-side and 0 sell-side disclosures on record, spanning 2022-10-13 to 2026-04-09.
Do insider buys in Korean stocks predict returns?: Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.